Quarterly report · Q2
2689.TEDINET S100Q89E
Period2022-07-01 → 2022-12-31
Filed2023-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥53.7bn | 2022-07-01 → 2022-12-31 | Cons. | Net sales |
| Revenue | ¥108.0bn | 2021-07-01 → 2022-06-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥53.0bn | 2021-07-01 → 2021-12-31 | Cons. | Net sales |
| Operating income | ¥854m | 2022-07-01 → 2022-12-31 | Cons. | Operating income |
| Operating income | ¥787m | 2021-07-01 → 2021-12-31 | Cons. | Operating income |
| Ordinary income | ¥859m | 2022-07-01 → 2022-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥2.1bn | 2021-07-01 → 2022-06-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥803m | 2021-07-01 → 2021-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥857m | 2022-07-01 → 2022-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥783m | 2021-07-01 → 2021-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥548m | 2022-07-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.5bn | 2021-07-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥533m | 2021-07-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥548m | 2022-07-01 → 2022-12-31 | Cons. | Profit loss |
| Net income | ¥533m | 2021-07-01 → 2021-12-31 | Cons. | Profit loss |
| Total assets | ¥40.6bn | at 2022-12-31 | Cons. | Assets |
| Total assets | ¥40.0bn | at 2022-06-30 | Cons. | Assets |
| Total assets | ¥41.6bn | at 2021-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥31.3bn | at 2022-12-31 | Cons. | Liabilities |
| Total liabilities | ¥30.9bn | at 2022-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥9.3bn | at 2022-12-31 | Cons. | Net assets |
| Net assets / equity | ¥9.1bn | at 2022-06-30 | Cons. | Net assets |
| Net assets / equity | ¥8.3bn | at 2021-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.6bn | at 2022-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.2bn | at 2022-06-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.6bn | at 2022-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.1bn | at 2022-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.1bn | at 2021-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.1bn | at 2021-06-30d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥1.9bn | 2022-07-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.4bn | 2021-07-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥867m | 2021-07-01 → 2021-12-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥143m | 2022-07-01 → 2022-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥212m | 2021-07-01 → 2022-06-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥278m | 2021-07-01 → 2021-12-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.5bn | 2022-07-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.2bn | 2021-07-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥2.2bn | 2021-07-01 → 2021-12-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥91.09 | 2022-07-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥49.24 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥252.8 | 2021-07-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥87.57 | 2021-07-01 → 2021-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥58.75 | 2021-10-01 → 2021-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 22.9% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 22.8% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 20.0% | at 2021-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-07-01 → 2022-12-31 | −¥789m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-07-01 → 2022-12-31 | −¥789m |
| Reconciling Itemsreconciling | segment profit | 2022-07-01 → 2022-12-31 | −¥71m |
| jpcrp040300-q2r_E02928-000Care Nursing Goodsreportable segment | revenue | 2022-07-01 → 2022-12-31 | ¥1.2bn |
| jpcrp040300-q2r_E02928-000Care Nursing Goodsreportable segment | revenue external | 2022-07-01 → 2022-12-31 | ¥1.2bn |
| jpcrp040300-q2r_E02928-000Care Nursing Goodsreportable segment | revenue intersegment | 2022-07-01 → 2022-12-31 | ¥104,000 |
| jpcrp040300-q2r_E02928-000Care Nursing Goodsreportable segment | segment profit | 2022-07-01 → 2022-12-31 | ¥92m |
| jpcrp040300-q2r_E02928-000Medical Equipmentreportable segment | revenue | 2022-07-01 → 2022-12-31 | ¥50.7bn |
| jpcrp040300-q2r_E02928-000Medical Equipmentreportable segment | revenue external | 2022-07-01 → 2022-12-31 | ¥50.0bn |
| jpcrp040300-q2r_E02928-000Medical Equipmentreportable segment | revenue intersegment | 2022-07-01 → 2022-12-31 | ¥726m |
| jpcrp040300-q2r_E02928-000Medical Equipmentreportable segment | segment profit | 2022-07-01 → 2022-12-31 | ¥735m |
| jpcrp040300-q2r_E02928-000SPDreportable segment | revenue | 2022-07-01 → 2022-12-31 | ¥2.6bn |
| jpcrp040300-q2r_E02928-000SPDreportable segment | revenue external | 2022-07-01 → 2022-12-31 | ¥2.5bn |
| jpcrp040300-q2r_E02928-000SPDreportable segment | revenue intersegment | 2022-07-01 → 2022-12-31 | ¥64m |
| jpcrp040300-q2r_E02928-000SPDreportable segment | segment profit | 2022-07-01 → 2022-12-31 | ¥98m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-07-01 → 2022-12-31 | ¥54.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-07-01 → 2022-12-31 | ¥53.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-07-01 → 2022-12-31 | ¥789m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-07-01 → 2022-12-31 | ¥925m |
| Reconciling Itemsreconciling | revenue | 2021-07-01 → 2021-12-31 | −¥674m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-07-01 → 2021-12-31 | −¥674m |
| Reconciling Itemsreconciling | segment profit | 2021-07-01 → 2021-12-31 | −¥80m |
| jpcrp040300-q2r_E02928-000Care Nursing Goodsreportable segment | revenue | 2021-07-01 → 2021-12-31 | ¥1.2bn |
| jpcrp040300-q2r_E02928-000Care Nursing Goodsreportable segment | revenue external | 2021-07-01 → 2021-12-31 | ¥1.2bn |
| jpcrp040300-q2r_E02928-000Care Nursing Goodsreportable segment | revenue intersegment | 2021-07-01 → 2021-12-31 | ¥257,000 |
| jpcrp040300-q2r_E02928-000Care Nursing Goodsreportable segment | segment profit | 2021-07-01 → 2021-12-31 | ¥85m |
| jpcrp040300-q2r_E02928-000Medical Equipmentreportable segment | revenue | 2021-07-01 → 2021-12-31 | ¥50.2bn |
| jpcrp040300-q2r_E02928-000Medical Equipmentreportable segment | revenue external | 2021-07-01 → 2021-12-31 | ¥49.6bn |
| jpcrp040300-q2r_E02928-000Medical Equipmentreportable segment | revenue intersegment | 2021-07-01 → 2021-12-31 | ¥610m |
| jpcrp040300-q2r_E02928-000Medical Equipmentreportable segment | segment profit | 2021-07-01 → 2021-12-31 | ¥720m |
| jpcrp040300-q2r_E02928-000SPDreportable segment | revenue | 2021-07-01 → 2021-12-31 | ¥2.3bn |
| jpcrp040300-q2r_E02928-000SPDreportable segment | revenue external | 2021-07-01 → 2021-12-31 | ¥2.3bn |
| jpcrp040300-q2r_E02928-000SPDreportable segment | revenue intersegment | 2021-07-01 → 2021-12-31 | ¥63m |
| jpcrp040300-q2r_E02928-000SPDreportable segment | segment profit | 2021-07-01 → 2021-12-31 | ¥61m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-07-01 → 2021-12-31 | ¥53.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-07-01 → 2021-12-31 | ¥53.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-07-01 → 2021-12-31 | ¥674m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-07-01 → 2021-12-31 | ¥866m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 508
| Item | Context | Value | Unit |
|---|---|---|---|
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |